XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash Flows from Operating Activities:    
Net income (loss) $ (6,698,242) $ 21,721,858
Adjustments to reconcile net income (loss) to net cash flows used in operating activities:    
Depreciation and amortization 493,395 55,422
Stock-based compensation 394,749 326,164
Change in fair value of warrant derivative liabilities (148,171) (24,552,257)
Provision for inventory obsolescence 18,629 427,907
Provision for doubtful accounts receivable (150,636)
Change in fair value of contingent consideration promissory note 56,050
Increase (decrease) in:    
Accounts receivable – trade (744,521) 574,072
Accounts receivable – other 41,928 (379,472)
Inventories 234,987 (1,115,549)
Prepaid expenses (512,817) 200,027
Operating lease right of use assets 102,165 4,434
Other assets (2,529,277) (187,291)
Accounts payable 2,958,343 (478,608)
Accrued expenses (142,043) 69,630
Operating lease obligations (102,164) (15,451)
Income taxes payable 15,000
Contract liabilities 656,953 142,270
Net cash used in operating activities (6,055,672) (3,206,844)
Cash Flows from Investing Activities:    
Purchases of furniture, fixtures and equipment (1,774,592) (77,011)
Additions to intangible assets (37,127) (22,263)
Cash paid for acquisition of Medical Billing Company (1,153,627)
Cash paid for asset acquisition from Medical Billing Company (230,000)
Net cash used in investing activities (3,195,346) (99,274)
Cash Flows from Financing Activities:    
Repurchase and cancellation of common stock (2,063,768)
Distribution to noncontrolling interest in consolidated subsidiary (15,692)
Net proceeds from sale of common stock in registered direct offerings 13,346,600
Proceeds from issuance of common stock upon exercise of pre-funded warrants 53,224,000
Principal payment on contingent consideration promissory notes (116,198)
Net cash provided by (used in) financing activities (2,195,658) 66,570,600
Net increase/(decrease) in cash and cash equivalents (11,446,676) 63,264,482
Cash, cash equivalents, beginning of period 32,007,792 4,361,758
Cash, cash equivalents, end of period 20,561,116 67,626,240
Supplemental disclosures of cash flow information:    
Cash payments for interest 18,847
Cash payments for income taxes 9,969
Supplemental disclosures of non-cash investing and financing activities:    
Restricted common stock grant 715 450
Restricted common stock forfeitures 15 8
Amounts allocated to initial measurement of warrant derivative liabilities in connection to the warrants and pre-funded warrants 51,216,058
Issuance of contingent consideration promissory note for business and asset acquisitions 855,000
Assets acquired in business acquisitions 190,631
Goodwill acquired in business acquisitions 2,100,000
Liabilities assumed in business acquisitions $ 387,005